Compare Novo Nordisk A/S (NVO) vs Palo Alto Networks Inc (PANW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Palo Alto Networks Inc — how do they compare? Novo Nordisk A/S trades at $38.37 (market cap $165.31B), while Palo Alto Networks Inc trades at $414.51 (market cap $331.76B). The key difference: Palo Alto Networks Inc is far larger — about 2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays a 4.71% dividend while Palo Alto Networks Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and Palo Alto Networks Inc for 82 Days on average.
| NVO | PANW | |
|---|---|---|
Market Cap | $165.31B | $331.76B |
Volume | 11,432,838 | 3,886,927 |
Sector | Health | Technology |
52-Week High | $63.98 | $419.91 |
52-Week Low | $35.29 | $141.67 |
Typical Hold Time | 116 Days | 82 Days |
Enterprise Value | $179.56B | $331.19B |
Dividend Yield | 4.71% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Palo Alto Networks (PANW) trades at $405.41, down 3.45% today but maintains a bullish technical outlook with strong moving average signals. The company demonstrates robust revenue growth, reaching $9.22B in 2025, though net margins compressed to 2.67%. Recent AI security initiatives, including Unit 42 AI defense service, position PANW for continued growth in the cybersecurity sector.
PANW presents a mixed investment case with strong AI-driven growth potential offset by premium valuations (P/E 1,013.93, P/S 26.99). Analyst consensus remains strongly bullish (72% buy ratings) with a $398.70 price target. Key risks include valuation sensitivity and competitive pressures in the rapidly evolving cybersecurity landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Palo Alto Networks Inc
Palo Alto Networks is a pure-play cybersecurity vendor that sells security appliances, subscriptions, and support into enterprises, government entities, and service providers. The company's product portfolio includes firewall appliances, virtual firewalls, endpoint protection, cloud security, and cybersecurity analytics. The Santa Clara, California, firm was established in 2005 and sells its products worldwide.
Read more on PANW →
